Solventum Completes Acquisition of Wound Care Innovator Acera Surgical

On Dec. 23, Solventum completed its acquisition of Acera Surgical, a bioscience company that developed and commercialized fully engineered materials for regenerative wound care. Solventum, which had announced a definitive agreement to acquire Acera in November, is paying $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of “certain future milestones.” Acera was expected to generate approximately $90 million in sales in 2025.

Solventum said the move expands its MedSurg portfolio into the “fast-growing synthetic tissue matrices technology space, a part of the broader regenerative tissue matrices category within acute care settings.”

Acera, founded in 2013, provides synthetic treatment options for soft tissue repair via its proprietary electrospinning technology platform (watch Acera’s two-minute video overview of its technology). Its Restrata products are currently available in the U.S. for treatment of difficult-to-heal, complex wounds in acute care settings.

"The addition of Acera's innovative synthetic tissue matrix technology complements our existing advanced wound care portfolio, enhancing the solutions our specialized commercial team can provide to clinicians and decision makers in acute care settings,” said Solventum CEO Bryan Hanson. In November, Hanson called regenerative wound care “an exciting and fast-growing space” and lauded Acera’s “innovative technology to meet a significant unmet need in acute wound care.”